A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Mar 2017 Planned End Date changed from 1 Oct 2014 to 1 Oct 2017.
- 29 Mar 2017 Planned primary completion date changed from 1 Apr 2014 to 1 Jul 2017.
- 29 Mar 2017 Status changed from recruiting to active, no longer recruiting.